Sydney Jennings

Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.

Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.

New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.

The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.

Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.

The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.

Axsome has launched the SUMMIT phase 3 clinical trial evaluating AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.

A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.

New research underscores the need for public health interventions to improve the microbial and fiber content of diets in the US.

FDA awarded DT120 Breakthrough Therapy designation for MDD based on phase 3 data showing rapid, sustained improvement after one 100 μg dose.

Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.

US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.

FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.

A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.

Recent FDA actions include updates in HIV, influenza, narcolepsy, type 2 diabetes, and RSV prevention in high-risk children.

FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.

The proportion of US women aged 21 to 29 years who have never received cervical cancer screening more than doubled between 2005 and 2023, according to new data.

Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.

Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.

FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.

FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.

Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.

Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.

FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.

FDA authorized Aletta, a robotic venous blood collection device for supervised outpatient use, through the De Novo pathway.

FDA approved garetosmab for adults with FOP after phase 3 data showed fewer new HO lesions and clinician-assessed flare-ups vs placebo.

If approved, ecopipam would be the first new therapy indicated for pediatric patients with Tourette syndrome in more than 10 years.

Phase 3 LUCIDITY results showed avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% vs placebo in post-bariatric hypoglycemia.

Stepped reminders to PCPs and patients increased annual lung cancer screening adherence by 27.7 percentage points, according to new research.

A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.